Summary
Forty-five patients suffering from a major depression were administered zimeldine, amitriptyline or placebo (15 patients in each group) in a double-blind controlled study. In the zimeldine group, seven of the 14 patients treated for more than one week presented a toxic syndrome consisting in a severe prostration, fever, myalgias and arthralgias. In all patients presenting this syndrome, laboratory analyses revealed an elevation of alkaline phosphatase and of aspartate and alanine aminotransferases and a decrease in white blood cell and platelet counts. Three patients presented a mild proteinuria and hematuria. Although an immunological mechanism cannot be ruled out, several characteristics of this reaction suggest the formation of a metabolite of zimeldine with direct cellular toxicity. The relatively high starting dose of 200 mg/day of zimeldine administered in the present study and the increment to 300 mg/day after only seven days might have contributed to the high incidence of toxic reactions observed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ogren SO, Ross SB, Hall H, Hokm AC, Renyi AL (1981) The pharmacology of zimelidine: a 5-HT selective reuptake inhibitor. Acta Psychiatr Scand 63 [Suppl 290]: 127–151
Blier P, de Montigny C (1983) Electrophysiological investigations of the effect of repeated zimelidine administration on serotoninergic neurotransmission in the rat. J Neurosci 3: 1270–1278
Claghorn J, Gershon S, Goldstein BJ, Behrnetz S, Busil DF, Huitfeldt B (1983) A double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder. Neuro-Pharmacol Biol Psychiatr 7: 367–382
Coppen A, Rama Roa VA, Swade C, Wood K (1979) Zimelidine: a therapeutic and pharmacokinetic study in depression. Psychopharmacology 63: 199–202
Mondeth CH, Feighner JP (1983) A double-blind, controlled evaluation of zimelidine, imipramine and placebo in patients with primary affective disorders. Acta Psychiatr Scand 68 [Suppl 308]: 70–79
Montgomery SA, McAuley R, Rani SJ, Roy D, Montgomery B (1981) A double-blind comparison for zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand 63 [Suppl 290]: 314–327
Nilsson BS (1983) Adverse reactions in connection with zimelidine treatment – a review. Acta Psychiatr Scand [Suppl 308] 68: 115–119
Larsen FW, Hansen CE (1984) Zimeldine versus amitriptyline in endogenous depression. A double-blind study. Acta Psychiatr Scand 69: 343–349
American Psychiatric Association, Committee on Nomenclature and Statistics (1980) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Association. Washington, D.C.
Spitzer RL, Endicott J, Robins E (1978) Research diagnostic criteria. Arch Gen Psychiatr 35: 773–782
Hamilton MA (1960) A rating scale for depression. J Neurol Neurosurg Psychiat 23: 56
Caillé G, Kouassi E, de Montigny C (1983) Pharmacokinetic study of zimelidine using a new GLC method. Clin Pharmacokinet 8: 530–540
Clarkson AR, Seymour AE, Woodroffe AJ (1983) Primary renal hematuria: IgA nephropathy. In: Massry SG and Glassock RJ (eds). Textbook of nephrology, vol 1. Williams and Wilkins, Baltimore, pp 6.56
Griffin JP (1983) Drug-induced allergic and hypersensitivity reactions. Practitioner 227: 1283–1297
Kloss MW, Rosen GM, Rauckman EJ (1984) Cocaine-mediated hepatotoxicity. Biochem Pharmacol 33: 169–173
Pecknold J (1983) Discussion on adverse reactions to zimelidine treatment. Acta Psychiatr Scand 68 [Suppl 308]: 120–121
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Langlois, R., Cournoyer, G., de Montigny, C. et al. High incidence of multisystemic reactions to zimeldine. Eur J Clin Pharmacol 28, 67–71 (1985). https://doi.org/10.1007/BF00635710
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00635710